CE Mark for a New Generation Drug-Eluting Stent

Published date : 21 May 2013
Article date : 21 May 2013

Pharmabiz hosts an article that focuses on device manufacturer Biosensors International's receipt of the CE Mark for the BioMatrix NeoFlex. The device is the newest addition to the BioMatrix group of drug-eluting stents and features an advanced stent delivery system, improving pushability, trackability and crossability. According to the article, the stent offers a lower lesion entry profile than its predecessor although it retains the same combination of abluminal biodegradable polymer coating, proprietary limus drug Biolimus A9 (BA9) and flexible platform.

Results from the final 5 year LEADERS data demonstrated that BioMatrix Flex significantly reduced the risk of clinical events in the very late phase and showed a significant reduction in very late stent thrombosis (VLST), compared with Cypher Select.

The BioMatrix NeoFlex will be rolled out in all CE Mark global markets over the coming months. 

Source: Pharmabiz.com, 21 May 2013 

Back to Listings

WhichMedicalDevice is a FREE resource created by clinicians for clinicians.

Registration is free and gives you unlimited access to all of the content and features of this website.

Find out more...

Please sign in to view this content...

I have forgotten my password
Not a Member?

Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...

Why Register

Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.

We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.